M. Paone

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy

P. Ascierto, G. Ciliberto, E. Simeone, 2014, Oncoimmunology.

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

F. Fulciniti, G. Botti, P. Ascierto, 2014, Cancer Immunology, Immunotherapy.

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

G. Madonna, D. Mallardo, P. Ascierto, 2018, Journal of Immunotherapy for Cancer.

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

D. Mallardo, P. Ascierto, M. Del Vecchio, 2024, Nature communications.

Serious haematological toxicity during and after ipilimumab treatment: a case series

P. Ascierto, E. Simeone, N. Mozzillo, 2014, Journal of Medical Case Reports.

The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era

P. Ascierto, A. Sorrentino, L. Festino, 2019, Current Oncology Reports.

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

P. Ascierto, G. Ferrara, K. Peris, 2023, Frontiers in Oncology.

Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?

P. Ascierto, L. Licitra, C. Resteghini, 2023, The oncologist.